299. Cystic fibrosis Clinical trials / Disease details


Clinical trials : 1,696 Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-003772-37-IT
(EUCTR)
28/02/200623/06/2006A randomized, open label, multicentre, phase 3 trial to assess the safety of Tobramycin Inhalation Powder compared to TOBI in cystic fibrosis subjects - TIP003A randomized, open label, multicentre, phase 3 trial to assess the safety of Tobramycin Inhalation Powder compared to TOBI in cystic fibrosis subjects - TIP003 Cystic Fibrosis with presence of Pseudomonas aeruginosa infection
MedDRA version: 6.1;Level: PT;Classification code 10011763
INN or Proposed INN: Tobramycin
Product Name: Tobramycin Inhalation Powder TIP delivered by the T-326 Inhaler
Product Code: T-326
INN or Proposed INN: Tobramycin
CHIRON CORPORATION LIMITEDNULLNot RecruitingFemale: yes
Male: yes
500Phase 3Hungary;Germany;United Kingdom;Spain;Italy;Greece